NORTH CHICAGO, Ill. — A new, higher-dose formulation of a drug used to treat pancreatic disorders is now available, the drug's manufacturer said.
AbbVie announced the launch of the new formulation of Creon (pancrelipase) delayed-release capsules. The drug is used to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, removal of the pancreas and other conditions. The new strength is the highest-dose pancreatic enzyme replacement therapy available in the United States, AbbVie said.